Grapefruit USA Inc (GPFT)

[BuyOnDips]

BURBANK, CA, Apr 12, 2011 (MARKETWIRE via COMTEX) -- Imaging3(TM), Inc. (OTCBB:
IMGG), developer of a breakthrough medical imaging device that produces 3D
medical diagnostic images of virtually any part of the human body in real-time,
announced that the company's Chairman and CEO Dean Janes was interviewed on
Thursday, April 7, 2011, on MoneyTV, a business and investment oriented
television program. The interview focused on the company's three phased approach
for its FDA 510(k) submission for the Dominion Volumetric Imaging Scanner
(DViS).

Mr. Janes commented that the company has finalized its general resubmission
strategy after a thorough review with the company's FDA legal and technical
consulting team. Implementation of the strategy involves the following three
phased approach: First, the development of protocols for collecting comparison
imaging data. Second, with the assistance of the consultant team, meet with the
FDA to present the protocols with the goal of reaching consensus with the Agency
to help ensure a viable resubmission. The third and final phase is the
acquisition of images based on the approved imaging protocols and combining
those images and data with the overall package and final submission to the FDA.

The MoneyTV Episode can be viewed using these links
(http://www.moneytv.net/imgg14.mov, http://www.moneytv.net/volume15week14.htm)
and will be available on the Imaging3 website soon.

About Imaging3 Imaging3, Inc., founded in 1993, is a leading provider of
advanced technology medical imaging devices. The Company has developed a
breakthrough medical imaging device that produces 3D medical diagnostic images
of virtually any part of the human body in real-time. Because these 3D images
are instantly constructed in real-time, they can be used for any current or new
medical procedures in which multiple frames of reference are required to perform
medical procedures on or in the human body. Visit the company's website at
http://www.imaging3.com for more information

Safe Harbor Statement Matters discussed in this press release contain
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and similar
expressions identify such forward-looking statements. Actual results,
performance or achievements could differ materially from those contemplated,
expressed or implied by the forward-looking statements contained herein. These
forward-looking statements are based largely on the expectations of the Company
and are subject to a number of risks and uncertainties. These include, but are
not limited to, risks and uncertainties associated with: the impact of economic,
competitive and other factors affecting the Company and its operations, markets,
product, and distributor performance, technological obsolescence, competition
from other medical instrument(s) and imaging companies, lack of capital,
unexpected costs, failure or delay of FDA approval, absence of revenue, the
impact on the national and local economies resulting from an economic recession
or terrorist actions, and U.S. actions subsequently; unavailability of financing
for the Company or its customers, product malfunction and potential product
liability claims, and other factors detailed in reports filed by the Company.





Contact:

Imaging3, Inc.

Investor Relations

800-900-9729





SOURCE: Imaging3, Inc.





Copyright 2011 Marketwire, Inc., All rights reserved.

-0-




SUBJECT CODE: Financial Services:Investment Services and Trading

Manufacturing and Production:Machinery and Tools

Pharmaceuticals and Biotech:Equipment and Supplies

Medical and Healthcare:Healthcare

Medical and Healthcare:Medical Devices

Medical and Healthcare:Facilities and Providers